OMEPRAZOLE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H19N3O3S
Molecular Weight	345.4178
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cc1cnc(CS(=O)c2nc3ccc(cc3[nH]2)OC)c(C)c1OC

InChI

InChIKey=SUBDBMMJDZJVOS-UHFFFAOYSA-N

InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)

HIDE SMILES / InChI

Molecular Formula	C17H19N3O3S
Molecular Weight	345.4178
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202342s002lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022056lbl.pdf

Omeprazole belongs to a class of antisecretory compounds, which suppress gastric acid secretion by specific inhibition of the H+ /K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Omeprazole is used under brand names Prilosec and Losec for treatment of duodenal ulcer in adults, gastric ulcer in adults, Gastroesophageal Reflux Disease. In addition it used for maintenance of healing of erosive esophagitis in pediatric patients and adults and for treatment of pathological hypersecretory conditions in adults (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis). The most frequent significant adverse effects occurring in at least of patients include headache; upper respiratory tract infection, abdominal pain, diarrhea, back pain, weakness and rash.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 36 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10411559	Inhibitor 7701	Pathological hypersecretory conditions Gastroesophageal reflux disease Gastric ulcer Duodenal ulcer

Conditions

Condition	Modality	Targets	Highest Phase	Product
Heartburn 23 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=477cfda2-44cf-4d0e-bdc4-e30bf16bfea9	Primary		Approved 7997	NEXIUM 24HR Approved Use treats frequent heartburn (occurs 2 or more days a week) Launch Date 1395878400000
Duodenal ulcer 51 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022056lbl.pdf	Primary	Potassium-transporting ATPase	Approved 7997	PRILOSEC Approved Use PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults. Launch Date 1205971200000
Gastric ulcer 69 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022056lbl.pdf	Primary	Potassium-transporting ATPase	Approved 7997	PRILOSEC Approved Use PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults. Launch Date 1205971200000
Gastroesophageal reflux disease 56 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022056lbl.pdf	Primary	Potassium-transporting ATPase	Approved 7997	PRILOSEC Approved Use PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults. Launch Date 621734400000
Pathological hypersecretory conditions 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022056lbl.pdf	Primary	Potassium-transporting ATPase	Approved 7997	PRILOSEC Approved Use PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults. Launch Date 1205971200000

C_max

Value	Dose	Co-administered	Analyte	Population
7.5 μM EXPERIMENT https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021689Orig1s034lbl.pdf	40 mg 1 times / day multiple, intravenous dose: 40 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ESOMEPRAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
668 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf	1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		OMEPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
16.2 μM × h EXPERIMENT https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021689Orig1s034lbl.pdf	40 mg 1 times / day multiple, intravenous dose: 40 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	ESOMEPRAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1220 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf	1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OMEPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
1179 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2350532	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OMEPRAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1200 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217	20 mg single, oral dose: 20 mg route of administration: oral experiment type: single co-administered:	OMEPRAZOLE plasma	Homo sapiens population: healthy age: adults sex: food status:

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.4 h EXPERIMENT https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021689Orig1s034lbl.pdf	40 mg 1 times / day multiple, intravenous dose: 40 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:		ESOMEPRAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.58 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2350532	20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered:		OMEPRAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11563998/	unhealthy, 45.2 Health Status: unhealthy Age Group: 45.2 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/11563998/	Other AEs: Nausea, Diarrhoea... Other AEs: Nausea (7%) Diarrhoea (6%) Headache (3%) Sources: https://pubmed.ncbi.nlm.nih.gov/11563998/
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf	Other AEs: Headache, Abdominal pain... Other AEs: Headache (6.9%) Abdominal pain (5.2%) Nausea (4%) Diarrhea (3.7%) Vomiting (3.2%) Flatulence (2.7%) Esophageal acid reflux (1.9%) Upper respiratory infection (1.9%) Constipation (1.5%) Dizziness (1.5%) Rash (1.5%) Asthenia (1.3%) Back pain (1.1%) Cough (1.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1172 substrate 1470	inhibitor 1318 substrate 865	inhibitor 1421

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT3 570 CYP2C19 1215 CYP2B6 679 CYP2C8 761 CYP1A2 1268 BCRP 574 P-gp 1089 OATP1B1 698 OAT1 547 MATE1 290 MATE2 258 OCT2 582 OCT1 473 OCT3 139	CYP2C19 830 P-gp 1223 CYP2C8 586 CYP2C18 143	CYP1A2 618 CYP1A1 98 MRP3 55 CYP1B1 50

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2C19 1277	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22648560/ \| https://pubmed.ncbi.nlm.nih.gov/30845361/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022101s014021957s017021153s050lbl.pdf	strong [IC50 3.7 uM]	yes (co-administration study) Comment: Esomeprazole administration resulted in a significant increase (1.67‐fold) in the AUC0–∞ of proguanil and a significant decrease (0.522‐fold) in that of cycloguanil Sources: https://pubmed.ncbi.nlm.nih.gov/22648560/ \| https://pubmed.ncbi.nlm.nih.gov/30845361/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022101s014021957s017021153s050lbl.pdf
CYP1A2 1406	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22648560/	weak [IC50 >40 uM]
CYP2B6 845	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22648560/	weak [IC50 >40 uM]
CYP2C8 810	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22648560/	weak [IC50 >40 uM]
CYP2C9 1362	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22648560/	weak [IC50 >40 uM]
CYP2D6 1455	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22648560/	weak [IC50 >40 uM]
CYP3A4 1462	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22648560/	weak [IC50 >40 uM]
CYP1A2 1406	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/16248835/ \| https://pubmed.ncbi.nlm.nih.gov/10584979/	weak [Ki 150 uM]	weak (co-administration study) Comment: Omeprazole exerts a concentration-dependent inhibition of CYP1A2 activity in man. However, even after single oral doses up to 80 mg, this effect is weak and without clinical relevance Sources: https://pubmed.ncbi.nlm.nih.gov/16248835/ \| https://pubmed.ncbi.nlm.nih.gov/10584979/
CYP3A4 1462	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/11334262/ \| https://pubmed.ncbi.nlm.nih.gov/16248835/	weak [Ki 367.5 uM]
CYP2D6 1455	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/11334262/	weak [Ki 745.1 uM]
OAT3 572	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/28801980/	yes [IC50 1.2 uM]	likely (co-administration study) Comment: The frequency of delayed MTX elimination in patients administered esomeprazole was 71.4% Sources: https://pubmed.ncbi.nlm.nih.gov/28801980/
OCT1 488	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/	yes [IC50 15.7 uM]
BCRP 639	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/19076159/	yes [IC50 17.6 uM]
P-gp 1255	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/11770010/	yes [IC50 17.7 uM]
OCT3 139	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/	yes [IC50 22 uM]
OAT1 551	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 4.32 uM]
OCT2 583	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/20053795/ \| https://pubmed.ncbi.nlm.nih.gov/21779389/	yes [IC50 6.7 uM]
OAT3 572	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 6.8 uM]
OATP1B1 713	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/25975815/	yes [IC50 84.3 uM]	unlikely (co-administration study) Comment: Coaministration with simvastatin acid unlikely results in DDIs Sources: https://pubmed.ncbi.nlm.nih.gov/25975815/
CYP2C19 1277	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/16248835/ \| https://pubmed.ncbi.nlm.nih.gov/11334262/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf	yes [Ki 7.1 uM]	yes (co-administration study) Comment: Omeprazole increased Cmax and AUC of cilostazol by 18% and 26% respectively Sources: https://pubmed.ncbi.nlm.nih.gov/16248835/ \| https://pubmed.ncbi.nlm.nih.gov/11334262/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf
CYP1A1 188	inducer 1333 Sources: https://pubmed.ncbi.nlm.nih.gov/10445394/	yes
CYP1A2 1406	inducer 1333 Sources: https://pubmed.ncbi.nlm.nih.gov/12623754/	yes
CYP1B1 64	inducer 1333 Sources: https://pubmed.ncbi.nlm.nih.gov/12623754/	yes
CYP2C9 1362	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/11334262/ \| https://pubmed.ncbi.nlm.nih.gov/16248835/	yes
MATE1 291	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/20053795/ \| https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.2020.34.s1.09069	yes
MATE2 258	inhibitor 2614 Sources: https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.2020.34.s1.09069	yes
MRP1 129	supressor 128 Sources: https://pubmed.ncbi.nlm.nih.gov/30349304/	yes
P-gp 1255	supressor 128 Sources: https://pubmed.ncbi.nlm.nih.gov/33049093/ \| https://pubmed.ncbi.nlm.nih.gov/30349304/	yes
MRP3 200	inducer 1333 Sources: https://pubmed.ncbi.nlm.nih.gov/12538803/	yes	yes (expression study) Comment: livers of patients treated with omeprazole showed higher MRP3 protein expression Sources: https://pubmed.ncbi.nlm.nih.gov/12538803/

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C19 830	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/16093273/ \| https://pubmed.ncbi.nlm.nih.gov/9353355/ \| https://pubmed.ncbi.nlm.nih.gov/10901708/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf	major	yes (co-administration study) Comment: When voriconazole was given with omeprazole to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times and 4 times, respectively Sources: https://pubmed.ncbi.nlm.nih.gov/16093273/ \| https://pubmed.ncbi.nlm.nih.gov/9353355/ \| https://pubmed.ncbi.nlm.nih.gov/10901708/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf
CYP3A4 1470	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/16093273/ \| https://pubmed.ncbi.nlm.nih.gov/9353355/ \| https://pubmed.ncbi.nlm.nih.gov/10901708/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf	major	yes (co-administration study) Comment: Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased omeprazole serum levels. In a cross-over study in 12 healthy male subjects, St John’s wort, an inducer of CYP3A4, decreased the systemic exposure of omeprazole in CYP2C19 poor metabolisers (Cmax and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolisers (Cmax and AUC decreased by 49.6% and 43.9%, respectively) Sources: https://pubmed.ncbi.nlm.nih.gov/16093273/ \| https://pubmed.ncbi.nlm.nih.gov/9353355/ \| https://pubmed.ncbi.nlm.nih.gov/10901708/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf
CYP2C18 143	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/8894508/	minor
CYP2C8 586	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/8894508/	minor
CYP2C9 865	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/8894508/	minor
P-gp 1223	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/11770010/	no
CYP3A4 1470	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022101s014021957s017021153s050lbl.pdf	yes	yes (co-administration study) Comment: Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease esomeprazole concentrations Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022101s014021957s017021153s050lbl.pdf
CYP2C19 830	substrate 2752 Sources: https://www.ncbi.nlm.nih.gov/books/NBK100896/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022101s014021957s017021153s050lbl.pdf	yes	yes (pharmacogenomic study) Comment: Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease esomeprazole concentrations; The CYP2C19 isoenzyme exhibits polymorphism in the metabolism of esomeprazole, since some 3% of Caucasians and 15–20% of Asians lack CYP2C19 and are termed poor metabolizers. At steady state, the ratio of AUC in poor metabolizers to AUC in the rest of the population (normal metabolizers) is approximately 2 Sources: https://www.ncbi.nlm.nih.gov/books/NBK100896/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022101s014021957s017021153s050lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:50275	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50275
MolPort	MolPort-023-330-012	https://www.molport.com/shop/molecule-link/MolPort-023-330-012
ZINC	ZINC000004693574	http://zinc15.docking.org/substances/ZINC000004693574

PubMed

Title	Date	PubMed
Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction.	2000 Jul	10859152
Pharmacokinetic study of esomeprazole in the elderly.	2001	11286324
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.	2001	11173893
Antireflux surgery in children suffering from reflux-associated respiratory disease?	2001 Apr	11288221
Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus.	2001 Apr	11182211
Improved high performance liquid chromatographic analysis of omeprazole in human plasma.	2001 Feb	11272330
Gastroesophageal reflux disease and Barrett's esophagus.	2001 Feb	11272213
Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.	2001 Feb	11232672
[Usefulness of new triple therapy containing PPI].	2001 Feb	11218404
[Selection of antibiotics and planning of eradication for H. pylori infection].	2001 Feb	11218403
Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.	2001 Feb	11210394
Antibiotic-resistance patterns of Helicobacter pylori in Croatia: cohort study.	2001 Feb	11172654
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.	2001 Feb	11159802
The prescribing of acid suppressants prior to the endoscopic diagnosis of Barrett's oesophagus and oesophagitis.	2001 Feb	11148441
Analysis of gastrin receptor gene expression in proliferating cells in the neck zone of gastric fundic glands using laser capture microdissection.	2001 Feb 2	11165251
Management of GERD: medical versus surgical.	2001 Jan	11215853
Allergic contact dermatitis due to lansoprazole, a proton pump inhibitor.	2001 Jan	11156022
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.	2001 Jan	11136282
[Ulcer therapy with a new proton pump inhibitor. One week of treatment is enough].	2001 Jan 11	11216011
Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis.	2001 Jan 15	11212260
Biochemical properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-.	2001 Jan 5	11137874
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.	2001 Jan 8	11166003
Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?	2001 Jan-Feb	11208510
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.	2001 Mar	11303370
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.	2001 Mar	11280530
Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.	2001 Mar	11256484
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.	2001 Mar	11207517
Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.	2001 Mar	11207509
Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment.	2001 Mar	11171816
Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.	2001 Mar 6	11242498
New OTC drugs and devices 2000: a selective review.	2001 Mar-Apr	11297337
Microsatellite instability at D18S61 is associated with no regression of gastric mucosa-associated lymphoid tissue lymphoma after Helicobacter pylori eradication.	2001 Mar-Apr	11182043

Patents

Sample Use Guides

In Vivo Use Guide

The drug is administered orally, once daily. The dose depends on the condition treated.

Route of Administration: Oral

In Vitro Use Guide

Pretreatment of omeprazole (10-6 - 10-4M) dose-dependently inhibits neutrophil adherence and respiratory burst induced by H. pylori. These evidences imply that omeprazole may exhibit a beneficial effect on H. pylori-associated gastric mucosal damage caused by activated neutrophils.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:00:46 UTC 2021` Edited by `admin` on `Fri Jun 25 21:00:46 UTC 2021`
Record UNII	KG60484QX9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OMEPRAZOLE

Official Name

English

OMEPRAZOLE [JAN]

Common Name

English

OMEPRAZOLE COMPONENT OF ZEGERID

Common Name

English

5-METHOXY-2-(((4-METHOXY-3,5,-DIMETHYL-2-PYRIDINYL)-METHYL)SULPHINYL)-1H-BENZIMIDAZOLE

Common Name

English

NSC-759192

Code

English

NSC-751450

Code

English

1H-BENZIMIDAZOLE, 5-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-

Systematic Name

English

OMEPRAZOLE COMPONENT OF YOSPRALA

Brand Name

English

OMEPRAZOLE [USP]

Common Name

English

OMEPRAZOLE [USP-RS]

Common Name

English

OMEPRAZOLE [USP MONOGRAPH]

Common Name

English

OMEPRAZOLE [HSDB]

Common Name

English

OMEPRAZOLE [MART.]

Common Name

English

LOSEC

Brand Name

English

H-168/68

Code

English

5-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDYL)METHYL)SULFINYL)BENZIMIDAZOLE

Systematic Name

English

OMEPRAZOLE [MI]

Common Name

English

OMEPRAZOLE [GREEN BOOK]

Common Name

English

ZEGERID COMPONENT OMEPRAZOLE

Common Name

English

OMEPRAZOLE [WHO-DD]

Common Name

English

(RS)-6-METHOXY-2-((4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YL) METHYLSULFINYL)-1H-BENZO(D)IMIDAZOLE

Systematic Name

English

OMEPRAZOLE [INN]

Common Name

English

H 168/68

Code

English

OMEPRAZOLE [VANDF]

Common Name

English

OMEPRAZOLE [ORANGE BOOK]

Common Name

English

OMEPRAZOLE [USAN]

Common Name

English

YOSPRALA COMPONENT OMEPRAZOLE

Brand Name

English

Classification Tree Code System Code

WHO-ATC

A02BD05